论文部分内容阅读
目的评估人附睾分泌蛋白4(HE4)判断卵巢癌复发的灵敏度和特异度。方法 30例上皮性卵巢癌患者作为研究组,经过满意的肿瘤细胞减灭术和术后正规化疗后血清HE4和糖类抗原125(CA125)均降至正常。同时选取30例良性附件手术患者作为对照组。定期进行血清HE4和CA125检测,观察HE4判断卵巢癌复发的灵敏度和特异度。结果 CA125诊断卵巢癌复发的灵敏度和特异度分别为73.33%和86.67%。HE4诊断卵巢癌复发的灵敏度和特异度分别为86.67%和93.33%。HE4+CA125联合诊断卵巢癌复发的灵敏度和特异度分别为93.33%和93.33%。结论 HE4判断卵巢癌术后复发优于CA125,两者联合检测灵敏度、特异度更高。
Objective To assess the sensitivity and specificity of human epididymal secreted protein 4 (HE4) in determining the recurrence of ovarian cancer. Methods Thirty patients with epithelial ovarian cancer were enrolled in the study. Serum levels of HE4 and carbohydrate antigen 125 (CA125) were both reduced to normal after satisfactory cytoreductive surgery and postoperative formal chemotherapy. At the same time, 30 patients with benign appendages were selected as the control group. Periodic serum HE4 and CA125 detection, observation of HE4 to determine the sensitivity and specificity of ovarian cancer recurrence. Results The sensitivity and specificity of CA125 in the diagnosis of ovarian cancer recurrence were 73.33% and 86.67%, respectively. The sensitivity and specificity of HE4 in the diagnosis of ovarian cancer recurrence were 86.67% and 93.33%, respectively. The sensitivity and specificity of HE4 + CA125 in the diagnosis of ovarian cancer recurrence were 93.33% and 93.33%, respectively. Conclusions HE4 is superior to CA125 in determining postoperative recurrence of ovarian cancer. The sensitivity and specificity of combined detection of HE4 and HE125 are higher.